RxDoctor Payments DataLook up a doctor →

Mohammad Alsolaiman, MD

Gastroenterology · American Fork, UTNPI 1215986484

Payments from drug & device makers

$11,053in general payments, 2019–2025

Across 579 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Boston Scientific$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$831
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$498
  • Gilead$359
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$5705%
  • Food & beverage$10,29993%
  • Education$1852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,053 in reported general payments places this provider in the 75th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$140,775
Medicare patients
504
Services billed
1,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab28$754,844
LinzessLinaclotide31$18,519
Sucralfate59$10,653
Omeprazole581$10,456
Mesalamine16$5,410
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl180$3,433
Pantoprazole Sodium191$2,813
Esomeprazole Magnesium24$2,719
Rabeprazole Sodium62$2,190
SutabSod Sulf/Pot Chloride/Mag Sulf12$2,015
Budesonide DrBudesonide23$1,749
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl75$1,418
Azathioprine36$1,173
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine17$416
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg22$397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$831$754,84428 claims
AbbVieLinzess$3,608$18,51931 claims
Braintree Laboratories, Inc.Sutab$48$2,01512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 122 gastroenterology providers in Utah.

Other gastroenterology in American Fork

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →